25I Stock Overview
A biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmuPharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.001 |
| 52 Week High | UK£0.04 |
| 52 Week Low | UK£0.0002 |
| Beta | 1.58 |
| 11 Month Change | -93.33% |
| 3 Month Change | -92.00% |
| 1 Year Change | -93.75% |
| 33 Year Change | -98.19% |
| 5 Year Change | -99.62% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 25I | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -93.9% | -1.2% | -0.02% |
| 1Y | -93.8% | -20.1% | 8.2% |
Return vs Industry: 25I underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 25I underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 25I volatility | |
|---|---|
| 25I Average Weekly Movement | 1,344.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 25I's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 25I's weekly volatility has decreased from 1835% to 1344% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 5 | Tim McCarthy | www.immupharma.co.uk |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD.
ImmuPharma plc Fundamentals Summary
| 25I fundamental statistics | |
|---|---|
| Market cap | €7.84m |
| Earnings (TTM) | -€2.96m |
| Revenue (TTM) | n/a |
-93.2x
P/S Ratio-2.6x
P/E RatioIs 25I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 25I income statement (TTM) | |
|---|---|
| Revenue | -UK£69.96k |
| Cost of Revenue | UK£0 |
| Gross Profit | -UK£69.96k |
| Other Expenses | UK£2.39m |
| Earnings | -UK£2.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0059 |
| Gross Margin | 100.00% |
| Net Profit Margin | 3,519.61% |
| Debt/Equity Ratio | 0% |
How did 25I perform over the long term?
See historical performance and comparison